Seres Therapeutics reported a net loss of $19.9 million for Q1 2026, down from a net income of $32.7 million in Q1 2025, mainly due to the absence of a $50 million payment from Nestlé related to the VOWST sale. The company is progressing its live biotherapeutic pipeline, including SER-155 for immune checkpoint inhibitor-related enterocolitis and bloodstream infection prevention in blood cancer patients, and SER-603 for inflammatory bowel disease. Clinical data from an investigator-sponsored trial of SER-155 is expected soon, which could expand its therapeutic applications. Seres is actively seeking partnerships and funding to support further development and extend its cash runway beyond Q3 2026.
Ouster's stock surged nearly 8% in premarket trading after expanding its manufacturing partnership with Benchmark Electronics to scale production of its new REV8 digital lidar sensors. The REV8 sensors target industrial, robotics, automotive, and sma...
Safehold Inc. announced a common stock dividend of $0.177 per share for the second quarter of 2026, representing an annualized rate of $0.708 per share. The dividend will be paid on July 15, 2026, to shareholders of record as of June 30, 2026. Safeho...
Wedbush analyst Dan Ives praised SpaceX's IPO as a 'Goldilocks outcome' that reassures investors and supports the tech sector. The successful debut, with shares closing 19.3% above the IPO price, signals strong investor interest and paves the way for...
The global demand for critical minerals, especially lithium, is rising sharply due to energy transition, electric vehicles, and advanced manufacturing needs. Supply is constrained by maturing deposits, export restrictions, and concentration in a few ...
IREN Limited has completed the acquisition of Nostrum Group, a Spanish developer of grid-connected AI data centers, marking IREN's entry into the European market. This acquisition adds approximately 490MW of secured power capacity in Spain and includ...
